A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life. Muscle wasting is associated with reduced muscle strength in COPD subjects. In particular, weakness of peripheral muscles has been reported to play an important role in the reduced functional capacity and impaired exercise performance. The primary objective of this study is to investigate the effect of tesamorelin, in conjunction with exercise training, on lean body mass measured by dual energy x-ray absorptiometry (DXA) scan.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
3
Change From Baseline in Lean Body Mass at 6 Months
The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan
Time frame: 6 months
Change From Baseline in Exercise Capacity at 6 Months
Time frame: 6 months
Change From Baseline in Peripheral Muscle Strength at 6 Months
Time frame: 6 months
Change From Baseline in Patient-reported Outcomes at 6 Months
Time frame: 6 months
Adverse Events
Number and percentage of subjects with adverse events
Time frame: 6 months
COPD Exacerbations
Frequency and severity of COPD exacerbations
Time frame: 6 months
Plasma Glucose
Changes from baseline in fasting blood glucose
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.